US OptionsDetailed Quotes

TSVT240517C5000

Watchlist

0.19
0.000.00%

15min DelayClose May 17 11:22 ET

0.00High0.00Low

2seventy bio Stock Discussion

Trytosaveabit

Apr 25 06:11

$2seventy bio(TSVT.US)$ 2Seventy Bio Inc: Abecma (Idecabtagene Vicleucel, or Ide-Cel) Generated Approximately $52 Mln in U.S. Revenue During Q1 of 2024

Meltyy

Apr 9 10:48

FDA PDUFA Update…

🗓️ Last week’s PDUFAs:
$Supernus Pharmaceuticals(SUPN.US)$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US)$ & $Johnson & Johnson(JNJ.US)$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US)$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US)$ & $Bristol-Myers Squibb(BMY.US)$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US)$...

JESSE JAMES8832

Apr 9 06:43

2Seventy Bio Said Co, Bristol Myers Squibb Announced That FDA Approved Use Of Suspension Lentiviral Vector For Manufacturing Of Abecma

$2seventy bio(TSVT.US)$

JESSE JAMES8832

Apr 7 17:45

2seventy bio ( – ), the Healthcare sector company, was revisited by a Wall Street analyst on April 5. Analyst from Citi maintained a Buy rating on the stock and has a $12.00 price target.

$2seventy bio(TSVT.US)$

Trytosaveabit

Apr 5 08:21

$2seventy bio(TSVT.US)$ Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma
WSJ· 2 mins ago
Bristol Myers Squibb and 2seventy bio have won U.S. Food and Drug Administration approval for the earlier use of their Abecma gene therapy in the treatment course for people with the blood cancer multiple myeloma.
The companies on Friday said the FDA approved Abecma for the treatment of adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy, ...

Trytosaveabit

Apr 5 08:13

$2seventy bio(TSVT.US)$ At An Estimated Median Duration Of Follow-Up Of 15.9 Months At The Primary PFS Analysis, Abecma More Than Tripled The Primary Endpoint Of PFS Compared With Standard Regimens

JESSE JAMES8832

Apr 1 06:51

great news

$2seventy bio(TSVT.US)$ 2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to RegeneronApril 1, 2024 at 7:30 AM EDTPDF Version
- Company Now Exclusively Focused on Development and Commercialization of Abecma -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 1, 2024-- 2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all onc...

JESSE JAMES8832

Apr 1 06:41

2seventy Bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron

$2seventy bio(TSVT.US)$

JESSE JAMES8832

Mar 25 15:43

insider buys

$2seventy bio(TSVT.US)$

2F KILL CHEATERS

Mar 19 12:29

$2seventy bio(TSVT.US)$ +
(HOLO-LYT-PIXY...) KEEP BUYING, THEN THEY MUST GO DOWN (TO $1 AND DELETE) BECAUSE CHEATERS BLOCK SHORT = LAO TRAP TRADERS ONE WAY TO HELL 😭👹😡👊👎

No comment yet